Aleeza Abid
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aleeza Abid has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Mubashira Noor
Jinnah Sindh Medical University
3 shared publications - Muhammad Hassan Saeed
Department of Medicine, Jinnah Postgraduate Medical Center, Karachi, Pakistan
2 shared publications - Abdullah Saad
Sindh Medical College, Jinnah Sindh Medical University, Karachi, Pakistan
1 shared publication - Aliza Ahmed
Jinnah Sindh Medical University, Karachi, Pakistan
1 shared publication - Fakiha Ahmed Shah
Department of Medicine, Dr. Ziauddin Hospital, Karachi, Pakistan
1 shared publication - Ihsan Qamar
Faculty of Medicine, Spinghar University, Kabul, Afghanistan
1 shared publication
Latest Publications
- Open Access
- 31 May 2026
- Vol. 67 (1) , E7-E8
Addressing HPV Vaccine Hesitancy: A Crucial Step Toward Cervical Cancer Prevention in Pakistan.
- 31 May 2026
- Vol. 67 (1) , E7-E8
Open AccessAddressing HPV Vaccine Hesitancy: A Crucial Step Toward Cervical Cancer Prevention in Pakistan.
- Open Access
- 14 May 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (6) , 3404-3410
Zoliflodacin for uncomplicated gonorrhea: clinical evidence and implications beyond ceftriaxone plus azithromycin
Background: Globally, gonorrhea remains a common sexually transmitted infection that can lead to serious sexual and reproductive health complications if left untreated. Management has become more challenging due to the rapid progression of antimicrobial resistance in Neisseria gonorrhoeae . Currently, ceftriaxone-based regimens continue to be the standard treatment; however, the sudden demand for new treatment options is highlighted by concerns regarding resistance, the requirement for intramuscular administration, and the declining effectiveness of azithromycin. Objective: This review aims to evaluate the emerging role of zoliflodacin in the treatment of gonorrhea, with an emphasis on its potential to serve as a resistance-focused alternative, its oral administration, and its novel antimicrobial target. Methods: A narrative literature search was conducted using PubMed, Google Scholar, and Scopus to identify relevant studies published between 2016 and 2026. Randomized clinical trials, systematic reviews, narrative reviews, and international guidelines from the WHO, ECDC, and CDC were included. Literature selection was guided by SANRA. Results: A single 3-g oral dose of zoliflodacin appears to exhibit high microbiological cure rates for uncomplicated urogenital and rectal gonorrhea, and it is not less effective than ceftriaxone plus azithromycin for urogenital infections, according to Phase 2 and recent global Phase 3 clinical trials, which reported mild gastrointestinal side effects. Its mechanism of action provides limited evidence of resistance and is effective against multidrug-resistant Neisseria gonorrhoeae . Conclusion: Zoliflodacin represents a potentially effective oral alternative to the current ceftriaxone-based regimen for gonorrhea. With routine observation and careful stewardship, these findings may contribute significantly to the expansion of future treatment strategies.
- 14 May 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (6) , 3404-3410
Open AccessZoliflodacin for uncomplicated gonorrhea: clinical evidence and implications beyond ceftriaxone plus azithromycin
Background: Globally, gonorrhea remains a common sexually transmitted infection that can lead to serious sexual and reproductive health complications if left untreated. Management has become more challenging due to the rapid progression of antimicrobial resistance in Neisseria gonorrhoeae . Currently, ceftriaxone-based regimens continue to be the standard treatment; however, the sudden demand for new treatment options is highlighted by concerns regarding resistance, the requirement for intramuscular administration, and the declining effectiveness of azithromycin. Objective: This review aims to evaluate the emerging role of zoliflodacin in the treatment of gonorrhea, with an emphasis on its potential to serve as a resistance-focused alternative, its oral administration, and its novel antimicrobial target. Methods: A narrative literature search was conducted using PubMed, Google Scholar, and Scopus to identify relevant studies published between 2016 and 2026. Randomized clinical trials, systematic reviews, narrative reviews, and international guidelines from the WHO, ECDC, and CDC were included. Literature selection was guided by SANRA. Results: A single 3-g oral dose of zoliflodacin appears to exhibit high microbiological cure rates for uncomplicated urogenital and rectal gonorrhea, and it is not less effective than ceftriaxone plus azithromycin for urogenital infections, according to Phase 2 and recent global Phase 3 clinical trials, which reported mild gastrointestinal side effects. Its mechanism of action provides limited evidence of resistance and is effective against multidrug-resistant Neisseria gonorrhoeae . Conclusion: Zoliflodacin represents a potentially effective oral alternative to the current ceftriaxone-based regimen for gonorrhea. With routine observation and careful stewardship, these findings may contribute significantly to the expansion of future treatment strategies.
- Open Access
- 30 April 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (6) , 3589-3593
Primary osteogenic sarcoma of the sternum with intravascular invasion and rapid progression: a rare case report
Introduction and importance: Primary osteosarcoma of the sternum is a rare malignant bone tumor. Only a few cases have been documented, and most have been managed with chemotherapy and surgical intervention. Our case is distinctive due to the vascular invasion of the left brachiocephalic vein and lack of response to chemotherapy. Reporting this case contributes to the limited literature and highlights the diagnostic and therapeutic challenges associated with the management of primary sternal osteosarcoma. Case presentation: We describe a 37-year-old woman with a painful, progressively enlarging manubrial swelling. Imaging revealed a destructive sternal mass with mediastinal extension, pulmonary and nodal metastases, and a thrombus extending from the left brachiocephalic vein to the superior vena cava. Magnetic resonance imaging confirmed soft tissue infiltration, cardiac compression, and worsening pericardial effusion. Biopsy revealed malignant osteoid-forming cells with SATB2 positivity, confirming the diagnosis of primary sternal osteosarcoma. She received three cycles of doxorubicin and cisplatin, but her condition rapidly progressed. Regorafenib was initiated as salvage therapy; however, her condition worsened, and she died within 6 months of diagnosis. Clinical discussion: Primary osteosarcoma of the sternum is a rare and aggressive malignancy in adults. Imaging is crucial for staging and planning surgery. Standard treatment includes neoadjuvant chemotherapy with wide excision and reconstruction, whereas targeted therapies such as regorafenib may be considered for metastatic diseases. Conclusion: This case illustrates an exceptionally aggressive tumor complicated by vascular invasion and mediastinal involvement. This underscores the importance of early recognition to avoid diagnostic delays and demonstrates the limited efficacy of conventional chemotherapy in advanced disease. The use of regorafenib highlights the emerging systemic options that may be explored in refractory osteosarcoma. Our report emphasizes the urgent need for early diagnostic practices and a multidisciplinary approach to treatment.
- 30 April 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (6) , 3589-3593
Open AccessPrimary osteogenic sarcoma of the sternum with intravascular invasion and rapid progression: a rare case report
Introduction and importance: Primary osteosarcoma of the sternum is a rare malignant bone tumor. Only a few cases have been documented, and most have been managed with chemotherapy and surgical intervention. Our case is distinctive due to the vascular invasion of the left brachiocephalic vein and lack of response to chemotherapy. Reporting this case contributes to the limited literature and highlights the diagnostic and therapeutic challenges associated with the management of primary sternal osteosarcoma. Case presentation: We describe a 37-year-old woman with a painful, progressively enlarging manubrial swelling. Imaging revealed a destructive sternal mass with mediastinal extension, pulmonary and nodal metastases, and a thrombus extending from the left brachiocephalic vein to the superior vena cava. Magnetic resonance imaging confirmed soft tissue infiltration, cardiac compression, and worsening pericardial effusion. Biopsy revealed malignant osteoid-forming cells with SATB2 positivity, confirming the diagnosis of primary sternal osteosarcoma. She received three cycles of doxorubicin and cisplatin, but her condition rapidly progressed. Regorafenib was initiated as salvage therapy; however, her condition worsened, and she died within 6 months of diagnosis. Clinical discussion: Primary osteosarcoma of the sternum is a rare and aggressive malignancy in adults. Imaging is crucial for staging and planning surgery. Standard treatment includes neoadjuvant chemotherapy with wide excision and reconstruction, whereas targeted therapies such as regorafenib may be considered for metastatic diseases. Conclusion: This case illustrates an exceptionally aggressive tumor complicated by vascular invasion and mediastinal involvement. This underscores the importance of early recognition to avoid diagnostic delays and demonstrates the limited efficacy of conventional chemotherapy in advanced disease. The use of regorafenib highlights the emerging systemic options that may be explored in refractory osteosarcoma. Our report emphasizes the urgent need for early diagnostic practices and a multidisciplinary approach to treatment.
- Open Access
- 13 January 2026
- Published by Taylor & Francis in The Journal of Maternal-Fetal & Neonatal Medicine
- Vol. 39 (1) , 2613552
Letter to the editor regarding the article: the effect of preterm premature rupture of membranes on neonatal outcomes in low-birth-weight infants: a retrospective study
- 13 January 2026
- Published by Taylor & Francis in The Journal of Maternal-Fetal & Neonatal Medicine
- Vol. 39 (1) , 2613552
Open AccessLetter to the editor regarding the article: the effect of preterm premature rupture of membranes on neonatal outcomes in low-birth-weight infants: a retrospective study
- Open Access
- 25 November 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (1) , 1078-1079
Post-COVID-19 interstitial cystitis and bladder dysfunction: a growing concern for public health
- 25 November 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (1) , 1078-1079
Open AccessPost-COVID-19 interstitial cystitis and bladder dysfunction: a growing concern for public health